{"hands_on_practices": [{"introduction": "Successfully interrupting poliovirus transmission relies on meticulously planned vaccination campaigns. This practice problem demystifies the operational logistics behind a Supplemental Immunization Activity (SIA), translating high-level public health goals into tangible resource requirements. By working through this scenario [@problem_id:4993771], you will learn how to use core parameters like population size, vaccine efficacy, and coverage targets to calculate the necessary number of vaccine doses and teams, a fundamental skill for any public health program manager.", "problem": "A district is planning a series of Supplemental Immunization Activities (SIA) for polio using Oral Polio Vaccine (OPV) to interrupt transmission among children younger than five years. The district population is $1.60 \\times 10^{6}$, and the proportion of children younger than five years is $0.12$. Each SIA round aims to vaccinate a fraction $r$ of the eligible children, with $r = 0.90$. The per-dose probability that a vaccinated child becomes immune (vaccine take, that is, vaccine efficacy at the individual dose level) is $e = 0.60$. Assume independence of vaccination opportunities and vaccine take across rounds, and that once a child becomes immune, they remain immune. The programâ€™s objective is to achieve at least $0.95$ immune coverage in the under-five population through repeated SIA rounds.\n\nOperational parameters are as follows: each vaccination team can vaccinate $120$ children per day, and each SIA round lasts $4$ days. Vaccine wastage (including spillage, cold-chain loss, and open-vial wastage) is $0.10$ per round, assumed to apply to doses procured.\n\nUsing foundational definitions of coverage as the probability of a child being vaccinated in a round, and vaccine efficacy as the probability that vaccination confers immunity in that round, derive the minimum number of SIA rounds required to achieve at least $0.95$ immune coverage. Then, compute:\n- the total number of OPV doses that must be procured across all rounds, accounting for wastage, and\n- the number of vaccination teams required per round to meet the per-round operational coverage.\n\nExpress the final dose quantity as a count of doses and the team requirement as a count of teams. Present your final answer as a row matrix containing two entries: the first entry is the total number of doses to procure across all rounds, and the second entry is the number of teams required per round. No rounding is required beyond exact arithmetic, and no units are to be included in the final boxed matrix.", "solution": "The problem is assessed to be valid as it is scientifically grounded in public health principles, well-posed, objective, and provides a complete and consistent set of parameters for a solvable model.\n\nThe solution is derived through a sequence of calculations based on the provided data.\n\nFirst, we identify and list the given parameters, ensuring all mathematical entities are formatted in LaTeX.\n- Total district population: $N_{total} = 1.60 \\times 10^{6}$.\n- Proportion of children younger than five years: $p_{u5} = 0.12$.\n- Per-round vaccination coverage target: $r = 0.90$.\n- Per-dose vaccine efficacy (probability of immunization given vaccination): $e = 0.60$.\n- Target immune coverage in the under-five population: $I_{target} = 0.95$.\n- Children vaccinated per team per day: $C_{team\\_day} = 120$.\n- Duration of one SIA round: $T_{round} = 4$ days.\n- Vaccine wastage rate: $W = 0.10$.\n\nThe first step is to calculate the total number of children in the target age group (under five years).\n$$N_{u5} = N_{total} \\times p_{u5} = (1.60 \\times 10^{6}) \\times 0.12 = 192000$$\nThis is the total eligible population for the vaccination campaign.\n\nNext, we determine the minimum number of SIA rounds required. Let $k$ be the number of rounds. The problem states that the rounds are independent events. For a single child in a single round, the probability of being successfully vaccinated and becoming immune is the product of the coverage probability $r$ and the vaccine efficacy $e$.\n$$P(\\text{immune in one round}) = r \\times e = 0.90 \\times 0.60 = 0.54$$\nThe probability that a child does not become immune in one round is therefore:\n$$P(\\text{not immune in one round}) = 1 - (r \\times e) = 1 - 0.54 = 0.46$$\nAfter $k$ independent rounds, the probability that a child has not become immune is this single-round failure probability raised to the power of $k$.\n$$P(\\text{not immune after } k \\text{ rounds}) = (1 - re)^k = (0.46)^k$$\nThe immune coverage after $k$ rounds, $I_k$, is the complement of this probability.\n$$I_k = 1 - (1 - re)^k$$\nThe objective is to achieve an immune coverage of at least $0.95$. We set up the inequality:\n$$I_k \\ge I_{target}$$\n$$1 - (0.46)^k \\ge 0.95$$\nRearranging the inequality to solve for $k$:\n$$(0.46)^k \\le 1 - 0.95$$\n$$(0.46)^k \\le 0.05$$\nTo solve for $k$, we take the natural logarithm of both sides. As $\\ln(x)$ is an increasing function, the direction of the inequality is preserved.\n$$\\ln((0.46)^k) \\le \\ln(0.05)$$\n$$k \\ln(0.46) \\le \\ln(0.05)$$\nSince $0.46  1$, $\\ln(0.46)$ is a negative number. Dividing by $\\ln(0.46)$ reverses the inequality sign.\n$$k \\ge \\frac{\\ln(0.05)}{\\ln(0.46)}$$\nNumerically, this is:\n$$k \\ge \\frac{-2.99573...}{-0.77653...} \\approx 3.8578...$$\nSince the number of rounds $k$ must be an integer, we must conduct a minimum of $4$ rounds.\n$$k = \\lceil 3.8578... \\rceil = 4$$\n\nWith $k=4$ established, we can compute the logistical requirements.\n\nFirst, we calculate the number of children to be vaccinated in each round. This is the target coverage $r$ applied to the eligible population $N_{u5}$.\n$$N_{vacc\\_round} = N_{u5} \\times r = 192000 \\times 0.90 = 172800$$\nThis is the number of doses that must be successfully administered in each round.\n\nNext, we calculate the total number of doses to be procured. The number of procured doses must account for the wastage rate $W=0.10$. If $D_{round}$ is the number of doses procured for a round, then the number of usable doses is $D_{round} \\times (1 - W)$. This must equal the number of children to be vaccinated.\n$$D_{round} \\times (1 - W) = N_{vacc\\_round}$$\n$$D_{round} = \\frac{N_{vacc\\_round}}{1 - W} = \\frac{172800}{1 - 0.10} = \\frac{172800}{0.90} = 192000$$\nSo, $192000$ doses must be procured for each of the $4$ rounds.\nThe total number of doses to be procured across all rounds is:\n$$D_{total} = k \\times D_{round} = 4 \\times 192000 = 768000$$\n\nFinally, we compute the number of vaccination teams required per round. Each team vaccinates $C_{team\\_day} = 120$ children per day. A round lasts $T_{round} = 4$ days. Therefore, the capacity of one team per round is:\n$$C_{team\\_round} = C_{team\\_day} \\times T_{round} = 120 \\times 4 = 480 \\text{ children per team per round}$$\nThe number of teams required, $T_{teams}$, is the total number of children to be vaccinated per round divided by the capacity of a single team per round.\n$$T_{teams} = \\frac{N_{vacc\\_round}}{C_{team\\_round}} = \\frac{172800}{480} = 360$$\nThus, $360$ teams are required for each of the $4$ rounds.\n\nThe problem asks for a final answer as a row matrix containing two entries: the total number of OPV doses to procure across all rounds, and the number of vaccination teams required per round.\n1. Total doses procured: $768000$.\n2. Teams required per round: $360$.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n768000  360\n\\end{pmatrix}\n}\n$$", "id": "4993771"}, {"introduction": "The final phase of polio eradication faces the challenge of vaccine-derived polioviruses, a rare side effect of the oral polio vaccine (OPV). This exercise explores the quantitative reasoning behind the strategic shift to novel oral polio vaccines (nOPV), which are engineered for greater genetic stability. This practice [@problem_id:4993775] allows you to perform a risk-benefit analysis by calculating the expected reduction in paralytic cases, thereby appreciating the data-driven basis for major global health policy decisions.", "problem": "A global health program is evaluating the expected reduction in harm, measured as paralytic poliomyelitis cases per $100{,}000$ doses, when switching from the monovalent Sabin type $2$ oral poliovirus vaccine to the novel Oral Poliovirus Vaccine type $2$ (nOPV2). Harm is defined as the expected number of paralytic poliomyelitis cases attributable to two pathways: Vaccine-Associated Paralytic Poliomyelitis (VAPP) and outbreaks of circulating Vaccine-Derived Poliovirus type $2$ (cVDPV2) seeded by vaccine virus.\n\nAssume the following scientifically plausible and self-consistent scenario:\n- Vaccine-Associated Paralytic Poliomyelitis (VAPP) is a rare adverse event occurring with probability per dose $r_{V}$, yielding one paralytic case when it occurs. Under Sabin type $2$, the per-dose risk is $r_{V,S} = \\frac{1}{2.4 \\times 10^{6}}$. Under nOPV2, the per-dose VAPP risk is $r_{V,N} = 0.10 \\times r_{V,S}$.\n- A cVDPV2 outbreak is seeded with probability per $100{,}000$ doses, denoted $p_{\\text{seed}}^{(100k)}$, and when seeded, yields an expected $E$ paralytic cases in the population before being controlled. Under Sabin type $2$, the seeding probability per $100{,}000$ doses is $p_{\\text{seed},S}^{(100k)} = 1.5 \\times 10^{-3}$. Under nOPV2, the seeding probability is $p_{\\text{seed},N}^{(100k)} = 0.15 \\times p_{\\text{seed},S}^{(100k)}$. The expected paralytic cases per seeded outbreak is $E = 50$.\n\nAssume independence between VAPP events and cVDPV2 seeding, and apply the definition of expected value from probability theory to compute expected harm per $100{,}000$ doses for each vaccine option as the sum of expected VAPP cases and expected cVDPV2 cases. Using only these assumptions and definitions, derive from first principles and compute the expected harm reduction per $100{,}000$ doses when switching from Sabin type $2$ to nOPV2, defined as the expected harm under Sabin type $2$ minus the expected harm under nOPV2.\n\nRound your final answer to three significant figures. Express the final value in cases per $100{,}000$ doses.", "solution": "The problem is evaluated to be scientifically grounded, well-posed, objective, and internally consistent. It provides all necessary information for a unique solution. Therefore, a reasoned derivation of the solution is presented below.\n\nThe objective is to compute the expected harm reduction per $100{,}000$ doses when switching from the Sabin type $2$ oral poliovirus vaccine (OPV) to the novel Oral Poliovirus Vaccine type $2$ (nOPV2). Harm is defined as the total expected number of paralytic poliomyelitis cases from two independent pathways: Vaccine-Associated Paralytic Poliomyelitis (VAPP) and circulating Vaccine-Derived Poliovirus type $2$ (cVDPV2). All calculations will be performed for a cohort of $N = 100{,}000$ administered doses.\n\nLet $H_S$ and $H_N$ be the total expected harm per $100{,}000$ doses for the Sabin vaccine and nOPV2, respectively. The harm reduction, $\\Delta H$, is defined as:\n$$ \\Delta H = H_S - H_N $$\n\nAccording to the problem definition, the total harm is the sum of the expected cases from VAPP and cVDPV2.\n$$ H = E[\\text{VAPP cases}] + E[\\text{cVDPV2 cases}] $$\n\nLet's first calculate the expected harm for the Sabin type $2$ vaccine, $H_S$.\n\nThe VAPP component of harm for Sabin, $H_{V,S}$, is the expected number of VAPP cases per $100{,}000$ doses. The per-dose risk of VAPP is given as $r_{V,S} = \\frac{1}{2.4 \\times 10^6}$. Since each VAPP event results in one case, the expected number of cases for $N = 100{,}000 = 10^5$ doses is the product of the number of doses and the per-dose risk.\n$$ H_{V,S} = N \\times r_{V,S} = 10^5 \\times \\frac{1}{2.4 \\times 10^6} = \\frac{10^5}{24 \\times 10^5} = \\frac{1}{24} $$\n\nThe cVDPV2 component of harm for Sabin, $H_{C,S}$, is the expected number of cVDPV2 cases per $100{,}000$ doses. The problem provides the probability of seeding an outbreak per $100{,}000$ doses, $p_{\\text{seed},S}^{(100k)} = 1.5 \\times 10^{-3}$, and the expected number of cases per seeded outbreak, $E = 50$. The expected number of cases from cVDPV2 is the product of the probability of an outbreak being seeded and the expected number of cases given that an outbreak is seeded.\n$$ H_{C,S} = p_{\\text{seed},S}^{(100k)} \\times E = (1.5 \\times 10^{-3}) \\times 50 = 75 \\times 10^{-3} = 0.075 $$\n\nThe total expected harm for the Sabin vaccine per $100{,}000$ doses is the sum of these two components:\n$$ H_S = H_{V,S} + H_{C,S} = \\frac{1}{24} + 0.075 $$\n\nNext, we calculate the expected harm for nOPV2, $H_N$.\n\nThe VAPP risk per dose for nOPV2 is $r_{V,N} = 0.10 \\times r_{V,S}$. The VAPP component of harm for nOPV2, $H_{V,N}$, per $100{,}000$ doses is:\n$$ H_{V,N} = N \\times r_{V,N} = N \\times (0.10 \\times r_{V,S}) = 0.10 \\times (N \\times r_{V,S}) = 0.10 \\times H_{V,S} $$\n$$ H_{V,N} = 0.10 \\times \\frac{1}{24} = \\frac{1}{240} $$\n\nThe cVDPV2 seeding probability per $100{,}000$ doses for nOPV2 is $p_{\\text{seed},N}^{(100k)} = 0.15 \\times p_{\\text{seed},S}^{(100k)}$. The cVDPV2 component of harm for nOPV2, $H_{C,N}$, is:\n$$ H_{C,N} = p_{\\text{seed},N}^{(100k)} \\times E = (0.15 \\times p_{\\text{seed},S}^{(100k)}) \\times E = 0.15 \\times (p_{\\text{seed},S}^{(100k)} \\times E) = 0.15 \\times H_{C,S} $$\n$$ H_{C,N} = 0.15 \\times 0.075 = 0.01125 $$\n\nThe total expected harm for nOPV2 per $100{,}000$ doses is the sum of its components:\n$$ H_N = H_{V,N} + H_{C,N} = \\frac{1}{240} + 0.01125 $$\n\nFinally, we compute the harm reduction, $\\Delta H$:\n$$ \\Delta H = H_S - H_N = (H_{V,S} + H_{C,S}) - (H_{V,N} + H_{C,N}) $$\n$$ \\Delta H = (H_{V,S} - H_{V,N}) + (H_{C,S} - H_{C,N}) $$\n\nWe can substitute the expressions for the nOPV2 components in terms of the Sabin components:\n$$ \\Delta H = (H_{V,S} - 0.10 \\times H_{V,S}) + (H_{C,S} - 0.15 \\times H_{C,S}) $$\n$$ \\Delta H = 0.90 \\times H_{V,S} + 0.85 \\times H_{C,S} $$\n\nNow, we substitute the calculated values for $H_{V,S}$ and $H_{C,S}$:\n$$ \\Delta H = 0.90 \\times \\left(\\frac{1}{24}\\right) + 0.85 \\times (0.075) $$\n$$ \\frac{0.90}{24} = \\frac{9}{240} = \\frac{3}{80} = 0.0375 $$\n$$ 0.85 \\times 0.075 = 0.06375 $$\n$$ \\Delta H = 0.0375 + 0.06375 = 0.10125 $$\n\nThe expected harm reduction is $0.10125$ cases per $100{,}000$ doses. The problem requires rounding this value to three significant figures. The first three significant figures are $1$, $0$, and $1$. The fourth digit is $2$, so we round down.\n$$ \\Delta H \\approx 0.101 $$\nThis value represents the expected number of paralytic poliomyelitis cases averted per $100{,}000$ doses administered by switching from Sabin type $2$ to nOPV2.", "answer": "$$\\boxed{0.101}$$", "id": "4993775"}, {"introduction": "In the real world, vaccination coverage is rarely uniform, and programs often use multiple types of vaccines, such as the oral polio vaccine (OPV) and the inactivated polio vaccine (IPV). This exercise demonstrates how to evaluate the overall effectiveness of such a mixed strategy at the population level. By calculating the cohort-level protection [@problem_id:4993743], you will synthesize data on vaccine efficacy and coverage to understand the distinct and combined impacts on preventing both paralysis and underlying infection, offering a nuanced view of population immunity.", "problem": "A district participating in the Global Polio Eradication Initiative deploys both Oral Polio Vaccine (OPV) and Inactivated Polio Vaccine (IPV) across its population. The objective is to quantify cohort-level effective protection against two endpoints: paralytic poliomyelitis (paralysis) and infection (including asymptomatic intestinal infection). Use the following context-appropriate foundations:\n\n- Vaccine efficacy for a specified endpoint is defined as the proportional reduction in the risk of that endpoint among vaccinated individuals relative to unvaccinated individuals.\n- When two vaccines act on the same endpoint via independent mechanisms, the probability that neither vaccine prevents the endpoint equals the product of the probabilities that each vaccine alone fails to prevent it.\n\nThe cohort is partitioned into mutually exclusive coverage groups with the following proportions: OPV-only, IPV-only, both OPV and IPV, and neither. Let these coverage levels be $c_{\\mathrm{O}} = 0.38$, $c_{\\mathrm{I}} = 0.22$, $c_{\\mathrm{B}} = 0.28$, and $c_{\\mathrm{N}} = 0.12$, respectively, where $c_{\\mathrm{O}} + c_{\\mathrm{I}} + c_{\\mathrm{B}} + c_{\\mathrm{N}} = 1$.\n\nVaccine efficacy parameters for the endpoints are:\n- For OPV: efficacy against paralysis $e_{\\mathrm{O},P} = 0.96$ and efficacy against infection $e_{\\mathrm{O},I} = 0.82$.\n- For IPV: efficacy against paralysis $e_{\\mathrm{I},P} = 0.92$ and efficacy against infection $e_{\\mathrm{I},I} = 0.35$.\n\nAssume that OPV and IPV act independently with respect to the same endpoint when administered together. Compute the cohort-level effective protection against paralysis and infection, defined as the expected fraction of the cohort protected against each endpoint. Report both quantities as decimals and round your answers to four significant figures. No percentage signs are permitted.", "solution": "The problem is first validated to ensure it is scientifically grounded, well-posed, and objective.\n\n### Step 1: Extract Givens\n- **Definition of Vaccine Efficacy ($e$):** Proportional reduction in risk of an endpoint in vaccinated individuals relative to unvaccinated individuals.\n- **Independence Assumption:** For two vaccines (OPV and IPV), the probability of failure for both is the product of their individual failure probabilities.\n- **Cohort Coverage Proportions:**\n  - OPV-only ($c_{\\mathrm{O}}$): $0.38$\n  - IPV-only ($c_{\\mathrm{I}}$): $0.22$\n  - Both OPV and IPV ($c_{\\mathrm{B}}$): $0.28$\n  - Neither ($c_{\\mathrm{N}}$): $0.12$\n  - The sum $c_{\\mathrm{O}} + c_{\\mathrm{I}} + c_{\\mathrm{B}} + c_{\\mathrm{N}} = 0.38 + 0.22 + 0.28 + 0.12 = 1$.\n- **Vaccine Efficacy Parameters:**\n  - **OPV:**\n    - Efficacy against paralysis ($e_{\\mathrm{O},P}$): $0.96$\n    - Efficacy against infection ($e_{\\mathrm{O},I}$): $0.82$\n  - **IPV:**\n    - Efficacy against paralysis ($e_{\\mathrm{I},P}$): $0.92$\n    - Efficacy against infection ($e_{\\mathrm{I},I}$): $0.35$\n- **Objective:** Compute the cohort-level effective protection against paralysis ($EP_P$) and infection ($EP_I$), defined as the expected fraction of the cohort protected against each endpoint.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, using standard definitions and concepts from epidemiology and vaccinology (vaccine efficacy, cohort coverage, independent action of vaccines). The provided efficacy values are realistic for OPV and IPV, reflecting their known immunological mechanisms (OPV's strong mucosal immunity against infection, and both vaccines' high efficacy against paralytic disease). The problem is well-posed, providing all necessary data and clear definitions to compute a unique solution. The coverage proportions sum to $1$, ensuring a consistent and complete partitioning of the cohort. The language is objective and precise.\n\n### Step 3: Verdict and Action\nThe problem is valid. A solution will be derived.\n\n### Solution Derivation\nThe cohort-level effective protection for a given endpoint is the weighted average of the protection levels in each of the four mutually exclusive coverage groups. The weight for each group is its proportion in the total cohort.\n\nLet $E$ represent the protection level (efficacy) for a subgroup against a specific endpoint (paralysis, $P$, or infection, $I$). The general formula for cohort-level effective protection, $EP$, is:\n$$EP = c_{\\mathrm{O}} E_{\\mathrm{O}} + c_{\\mathrm{I}} E_{\\mathrm{I}} + c_{\\mathrm{B}} E_{\\mathrm{B}} + c_{\\mathrm{N}} E_{\\mathrm{N}}$$\n\nWe must determine the protection level $E$ for each group and for each endpoint.\n\n1.  **Neither Group ($c_{\\mathrm{N}}$):** Individuals in this group receive no vaccine, so their vaccine-induced protection is zero.\n    $$E_{\\mathrm{N},P} = 0$$\n    $$E_{\\mathrm{N},I} = 0$$\n\n2.  **OPV-only Group ($c_{\\mathrm{O}}$):** The protection level is the efficacy of OPV.\n    $$E_{\\mathrm{O},P} = e_{\\mathrm{O},P} = 0.96$$\n    $$E_{\\mathrm{O},I} = e_{\\mathrm{O},I} = 0.82$$\n\n3.  **IPV-only Group ($c_{\\mathrm{I}}$):** The protection level is the efficacy of IPV.\n    $$E_{\\mathrm{I},P} = e_{\\mathrm{I},P} = 0.92$$\n    $$E_{\\mathrm{I},I} = e_{\\mathrm{I},I} = 0.35$$\n\n4.  **Both OPV and IPV Group ($c_{\\mathrm{B}}$):** The problem states that the vaccines act independently. If a vaccine has efficacy $e$, the probability it fails to protect is $1-e$. For two independent vaccines, the probability that both fail is the product of their individual failure probabilities. The combined protection (efficacy) is $1$ minus this combined failure probability.\n    For a generic endpoint $X \\in \\{P, I\\}$, the combined efficacy $E_{\\mathrm{B},X}$ is:\n    $$E_{\\mathrm{B},X} = 1 - (1 - e_{\\mathrm{O},X})(1 - e_{\\mathrm{I},X})$$\n    This is equivalent to $e_{\\mathrm{O},X} + e_{\\mathrm{I},X} - e_{\\mathrm{O},X}e_{\\mathrm{I},X}$.\n\n    -   For paralysis ($P$):\n        $$E_{\\mathrm{B},P} = 1 - (1 - e_{\\mathrm{O},P})(1 - e_{\\mathrm{I},P}) = 1 - (1 - 0.96)(1 - 0.92) = 1 - (0.04)(0.08) = 1 - 0.0032 = 0.9968$$\n    -   For infection ($I$):\n        $$E_{\\mathrm{B},I} = 1 - (1 - e_{\\mathrm{O},I})(1 - e_{\\mathrm{I},I}) = 1 - (1 - 0.82)(1 - 0.35) = 1 - (0.18)(0.65) = 1 - 0.117 = 0.883$$\n\nNow, we can compute the cohort-level effective protection for each endpoint.\n\n**Cohort-level Effective Protection against Paralysis ($EP_P$):**\n$$EP_P = c_{\\mathrm{O}} E_{\\mathrm{O},P} + c_{\\mathrm{I}} E_{\\mathrm{I},P} + c_{\\mathrm{B}} E_{\\mathrm{B},P} + c_{\\mathrm{N}} E_{\\mathrm{N},P}$$\nSubstituting the values:\n$$EP_P = (0.38)(0.96) + (0.22)(0.92) + (0.28)(0.9968) + (0.12)(0)$$\n$$EP_P = 0.3648 + 0.2024 + 0.279104 + 0$$\n$$EP_P = 0.846304$$\nRounding to four significant figures, we get $EP_P = 0.8463$.\n\n**Cohort-level Effective Protection against Infection ($EP_I$):**\n$$EP_I = c_{\\mathrm{O}} E_{\\mathrm{O},I} + c_{\\mathrm{I}} E_{\\mathrm{I},I} + c_{\\mathrm{B}} E_{\\mathrm{B},I} + c_{\\mathrm{N}} E_{\\mathrm{N},I}$$\nSubstituting the values:\n$$EP_I = (0.38)(0.82) + (0.22)(0.35) + (0.28)(0.883) + (0.12)(0)$$\n$$EP_I = 0.3116 + 0.077 + 0.24724 + 0$$\n$$EP_I = 0.63584$$\nRounding to four significant figures, we get $EP_I = 0.6358$.\n\nThe two requested quantities are the cohort-level effective protection against paralysis and infection, respectively.", "answer": "$$\n\\boxed{\\begin{pmatrix} 0.8463  0.6358 \\end{pmatrix}}\n$$", "id": "4993743"}]}